Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Korean Diabetes Assoc. 2000 Oct;24(5):587-602. Korean. Clinical Trial.
Oh YS , Song YD , Lee MK , Kim YS , Son HY .
Department of Internal Medicine, College of Medicine, Chung-Ang University.
Department of Internal Medicine, College of Medicine,Yonsei University.
Department of Internal Medicine, College of Medicine,Sungkyunkwan University.
Department of Internal Medicine, College of Medicine,Kyung Hee University.
Department of Internal Medicine, College of Medicine,Catholic University.
Abstract

BACKGROUND: Beraprost sodium (BPS) is a new stable, orally active prostaglandin I2 analogue with antiplatelet and vasodilating properties. We performed an prospective, multicenter, open clinical trial to assess the efficacy and safety of BPS in type 2 diabetic patients complicated with arteriosclerosis obliterans (ASO). METHOD: We recruited 34 type 2 diabetic patients complicated with ASO at 5 different university hospitals. Patients received BPS 40 g tid for 6-week. Patients performed a subjective and objective assessment of treatment usefulness at 2- and 6-week. Safety was assessed by obtaining clinical data and history. RESULTS: There was a significant difference between before and after treatment for changes regarding the items "chillness", "numbness" and "rest pain". An improve ment in intermittent claudication distance at the 2-or 4-week interval was achieved. Ankle Pressure Index (API) was not statistically different. The side effects including fever, myalgia, indigestion were subtle and the patients' compliance is good. CONCLUSION: These results show that BSP is an effective and safe symptomatic treatment of Type 2 diabetic patients with ASO.

Copyright © 2019. Korean Association of Medical Journal Editors.